TSOI DD / NEWS / SS
Therapeutic Solutions International is focused on immune modulation
for the treatment of several specific diseases
As recently stated we have developed a nanoparticle formulation of cannabidiol that we will soon introduce to the US market - these nanoparticles of cannabidiol are in the range of 75-90nm and are highly concentrated at 200mg/ml. Simply stated, a clinical dose is 2 drops. This bottle of the filtered (.22um) product represents 8,000 doses. (oh yeah, that's the boss in the photo). This particular batch is headed wholesale into Mexico for distribution.
TSOI Is On the Right To Try Pathway for treatment, and prevention of :
Stage 1 - 4 Cancers (Tumor types), w/ StemVacs Dendritic Cell Vaccine / Immunotherapy Platform, and NanoStilbeneTM
CTE - (Chronic Traumatic Encephalopathy) w/ JadiCell MSCs , Autologous Neurogenic Stem Cell Banking, sRNA augmented stem cells, "Educated" Monocytes / Progenitors, and NeuroStilbene
TBI / mTBI - (Traumatic Brain Injury / mild TBI) w/ JadiCell MSCs , and NeuroStilbene
CRS - (Cytokine Release Syndrome) / Inflammation w/ NanoStilbeneTM
TSOI CEO Tim G Dixon receiving the Right To Try Leadership Award (Video) 12/19/18
Therapeutic Solutions International Announces the Appointment of
James Veltmeyer, MD as Chief Medical Officer
Oceanside, CA -- June 18, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) previously announced their plans to provide access to its clinical stage cancer immunotherapy product StemVacs under the Right To Try law signed by President Trump on May 30th 2018, and have appointed Dr. James Veltmeyer as Chief Medical Officer of their future planned cancer clinic.
"Having Dr. Veltmeyer head up our future "Right To Try Cancer Clinic", as well as all other clinical programs underway is a dream come true for TSOI," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "In his role as Chief of the Department of Family Medicine at Sharp Grossmont Hospital, where he currently provides senior leadership to over 200 physicians, Dr. Veltmeyer has developed skills that few ever do, allowing him to bring a wealth of experience in management and medicine to bear on our programs.
FDA Right to Try info for patients
Who is in charge of pre-approval access decisions ?
8 Biologics, 10 Nutraceuticals, 1 Pharmaceutical = 19
sRNA augmented stem cells http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/78834511/therapeutic-solutions-international-expands-chroni
JadiCell MSCs https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/78853508/therapeutic-solutions-international-signs-agreemen
Autologous Neurogenic Stem Cell banking http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79022244/therapeutic-solutions-international-continues-to-e
"Educated" Monocytes / Projenitors https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79095195/therapeutic-solutions-international-continues-to-e
Alpha Lipoic Acid https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/78013140/therapeutic-solutions-international-develops-micro
Cancer Metabolic DeTox http://www.marketwired.com/press-release/therapeutic-solutions-files-new-patent-on-targeting-tumor-microenvironment-through-nutraceutical-otc-pink-tsoi-2215015.htm
3 New Products distributed in Mexico under the Immun ET Label
4 nutraceutical products for sale online
Projuvenol, NanoStilbene, DermalStilbene (x2)
4 Biologics, 3 Nutraceuticals, 1 Pharmaceutical licensed to Pan Am Cancer Treatment Center in Mexico
StemVacs, innaMune, MemoryMune, BRS-001, Cancer Metabolic DeTox, NanoStilbene, IsoStilbene, LymphoBoost
Pan Am Cancer Treatment Center Introductory Tour Video
TSOI Products in Development
=https://www.facebook.com/tsoihome/ (description under new TSOI lab photos)
Look for many new exciting specialty products to come from these facilities
including combination compounds such as pterostilbene and cannabidiol, pterostilbene and alpha-lipoic-acid, pterostilbene and huperzine, all in nanoparticle formulations.
Therapeutic Solutions International Awards Distribution of NanoStilbene and Nano Cannabidiol in Mexico to Immun ET Laboratories, LLC.
NanoStilbene Shown to Enhance Anticancer Immunity in Cancer Patients through Modulation of Inflammatory Mediators
OCEANSIDE, CA -- May 6, 2019 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today a sales agreement for the exclusive distribution of NanoStilbene and Nano Cannabidiol throughout Mexico with Immun ET.
TSOI recently announced preliminary data for immune stimulation in advanced cancer patients with NanoStilbene, a nanoemulsion of nanoparticle pterostilbene that is taken orally. Daily treatment with NanoStilbene caused a reduction in serum levels of inflammatory markers TNF-alpha, IL-6, and CRP. Assessment of peripheral blood mononuclear cell ability to generate IFN-gamma subsequent to stimulation with anti-CD3 and anti-CD28 was increased. Additionally, NK cytotoxicity was augmented.
These results suggest that NanoStilbene may be a useful adjuvant to immunotherapy of cancer rescuing T cell and NK cell activities. Augmentation of NK cell function may stimulate efficacy of approved therapies that depend on an active NK compartment such as Herceptin, Rituximab, and Cetuximab.
The Nano Cannabidiol product we have produced is built upon the same nano particle platform as NanoStilbene. This provides for good protection and oral delivery system, the nanoemulsion for cannabidiol isolate uses the same low-energy emulsification method as NanoStilbene. Nanoemulsions are non-equilibrium systems and possess kinetic stability in a long period with a remarkable small droplet size (below 200 nm).
The cannabidiol isolate (which contains zero THC, and zero Terpenes) we place in the nanodroplet is free from air, light, and hard environment and contains 200mg of >99% pure isolate per milliliter of liquid. Typical clinical doses of cannabidiol are in the range of 15-20mg daily. 2 drops of our Nano Cannabidiol provides 20mg.
"We are pleased to make this announcement today for Immun ET Laboratories to have exclusive distribution rights for NanoStilbene and Nano Cannabidiol throughout all of Mexico" said Tim G Dixon CEO & President of Therapeutic Solutions International, Inc. "Having worked closely with the principal of Immun ET, Dr. Javier Lopez, for many years in advanced cancer studies where in 2015 we conducted our 10 patient StemVacs immunotherapy clinical trial, we are excited to continue our long-standing relationship further solidified by this award announced today."
"Immun ET is very excited to offer both of these nano particle compounds from TSOI to our customers in both their original form and in various blends together we are calling NanoVita and NanoVita Plus. Having the privilege to observe all of the work in developing NanoStilbene, essentially from bench to bedside, including a pharmacokinetic study and a clinical trial of advanced cancer patients, we have eagerly awaited this day to be able to provide this patented immune adjuvant to cancer patients in Mexico" said Dr. Javier Lopez, Chief Executive Officer of Immun ET Laboratories. "And in addition, having the ability to distribute exclusively their Nano Cannabidiol in Mexico as well, gives us two very potent and highly concentrated formulations to meet a variety of clinical needs" added Dr. Lopez.
Therapeutic Solutions International Continues to Refine NanoStilbene™ Formulation
NanoStilbene Shown to Reduce Tumor Necrosis Factor-a (TNF-a ) in Cancer Patients
TSOI NEWS HISTORY 5/1/18 - 1/22/19
AS - 2.5 B common , 5 M preferred - https://www.nvsos.gov/SOSEntitySearch/CorpDetails.aspx?lx8nvq=LvtIoYTPV6wB1RIovm008A%253d%253d&nt7=0
OS - 1,101,102,071
Restricted - 899,619,214
Unrestricted - 201,482,857
Held at DTC - 168,729,857
Float - 105,109,529
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=therapeutic+solutions+international&match=contains&action=getcompany
New Horizon Transfer Inc.
215-515 West Pender Street
Vancouver, BC V6B 6H5
E Commerce Sites
Disclaimer : All of the information presented in the IBOX , Stickies , or posts on this board , is based on individual opinions , and is not to be considered as a recommendation to buy , sell , or hold this stock .